News

GENova Biotherapeutics (GENova) has gained access to distribution channels for its drug targets through a recently-signed deal with Bridge BioResearch. Through a recent collaboration deal, the two companies

Pieris has entered into a collaboration agreement with Allergan that combines Pieris’ proprietary Anticalin technology with Allergan’s expertise in drug delivery and ophthalmic drug development with a goal

Symyx Technologies (Symyx) has joined SAFE-BioPharma Association. The membership enables Symyx to implement the SAFE-BioPharma digital signature standard for records signing to safe-guard critical scientific data. The membership

Orasi Medical has opened its new Tokyo office. The new office is expected to allow Orasi Medical to aid Japanese pharmaceutical companies in developing medicines for CNS diseases

Schering-Plough has revealed final results of a Saphris long-term schizophrenia relapse prevention clinical study. In the double-blind phase of the study, time to relapse or impending relapse, the

Celldex Therapeutics (Celldex) has reported the first patient dosing in a phase 1/2 study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1.

Mpex Pharmaceuticals (Mpex) has reported positive top line results from a phase 2b clinical trial with Aeroquin, a new aerosol formulation of levofloxacin delivered by an optimised Investigational

ARIAD reports result of first interim analysis of phase 3 SUCCEED trial of oral ridaforolimus, an investigational mTOR inhibitor, in metastatic sarcomas. The company said that the phase

CytRx has initiated dose escalation study with its oncology drug candidate tamibarotene combined with TRISENOX injection in patients with relapsed acute promyelocytic leukemia (APL). According to CytRx, there